Needham analyst Mayank Tandon maintains ExlService Holdings (NASDAQ:EXLS) with a Buy and raises the price target from $190 to $200.
Gossamer Bio Secures $160M Partnership with Chiesi Group to Accelerate Development of Pulmonary Hypertension Treatment, $486M Potential for Seralutinib Collaboration
Gossamer Bio, Inc. ("Gossamer") (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and
